# Revolution Medicines

Type: Company (RVMD)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/revolution-medicines
Canonical HTML page: https://getfinancebrief.com/entity/revolution-medicines

## Recent coverage (2 stories)

### Axsome Revenue Doubles to $617M; 3 Biotechs Returned 230% vs. S&P 9% in H1
2026-07-07 06:57:49 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Full story: https://getfinancebrief.com/story/biotech-beats-sp500-financial-analysis

### DAFNA Capital Trims Axogen Stake by $6.5M Following 71% Stock Surge
2026-03-22 04:28:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately 265,456 shares during the fourth quarter of 2025, a move valued at $6.53 million. Despite the trim, the hedge fund maintains a significant $15.6 million stake in the nerve-repair specialist, which has seen its stock price climb 71% over the past year.
Full story: https://getfinancebrief.com/story/dafna-capital-axogen-trim-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.